Gilead Sciences, Inc. Price Today
Gilead Sciences, Inc.
GILD
Healthcare
$98.14B
💰
Market Cap
17.8
💸
Price to Earnings
$4.4
🎉
EPS
+78
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
13 |
Strong Buy |
5 |
Hold |
19 |
Sell |
0 |
Strong Sell |
0 |
GILD Price Forecast Target
78.7 👉 104.3 +33%
GILD EPS Forecast
4.4 👉 6.5 +47%
Financials
Profit Margin
20 %
Revenue Growth
5.4 %
Dividend
$ 3.0
Held Percent
0.1% - Insiders
86.8% - Institutions
13.1% - Public
Major Fund Holders
-
💰 Blackrock Inc. $10.0B
-
💰 Vanguard Group Inc $8.9B
-
💰 Capital World Investors $6.0B
-
💰 Capital Research Global Investors $4.6B
-
💰 State Street Corporation $4.5B
Stock Ideas
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Steven Cohen Portfolio
Steven Cohen, the legendary trader and billionaire founder of Stamford-based SAC Capital, has established himself as a force to be reckoned with in the hedge fund industry. With a staggering net worth of $8 billion and an impressive $14 billion in …
Nelson Peltz Portfolio
Nelson Peltz is a renowned investor known for his astute investment strategies and activist approach. With a portfolio spanning diverse industries, Peltz strategically targets underperforming companies, advocating for changes that unlock their full …📮FAQ
Some Frequently Asked Questions.
The Gilead Sciences, Inc. industry is Drug Manufacturers—General
The Gilead Sciences, Inc. sector is Healthcare
The Gilead Sciences, Inc. forecasted predicted Price to Earnings PE ratio is 12.1
The Gilead Sciences, Inc. Price to Earnings PE ratio is 17.8
The Market Capitalization of Gilead Sciences, Inc. is $98.14B
There are total of 1244668657 float shares with 86.8% held by Institutions and 0.1% held by insiders
The MGilead Sciences, Inc. forecasted Earnings per Share EPS is $6.5
The Gilead Sciences, Inc. Earnings per Share EPS is 4.4
The Gilead Sciences, Inc. company has $21624000000 gross profits with 20 profit margins
The Gilead Sciences, Inc. Earnings Growth is -0.088% with -0.087% quarterly earnings growth
The Gilead Sciences, Inc. Revenue is $27381999616 with 0.054 revenue growth
The price target for Gilead Sciences, Inc. stock is $104.3 for the high target and $69.8 for the low target
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, with the following breakdown:
- Buy: 13
- Strong Buy: 5
- Hold: 19
- Sell: 0
- Strong Sell: 0
The Beta of Gilead Sciences, Inc. is 0.4
The dividend of Gilead Sciences, Inc. is $3.0
The dividend yield of Gilead Sciences, Inc. is 0.0381%
The biggest institutional and mutual fund holders of Gilead Sciences, Inc. stock are
- Blackrock Inc.
- Vanguard Group Inc
- Capital World Investors
- Capital Research Global Investors
The Gilead Sciences, Inc. ESG Score is 78, with the following breakdown:
- E: 0.03
- S: 14.04
- G: 8.01